Anterra Capital

Anterra Capital, established in 2013 and headquartered in Amsterdam, is a venture capital firm specializing in growth capital investments in the global food supply chain. They focus on fast-growing companies that commercialize novel technologies and services, aiming to make the food supply chain safer, more efficient, and sustainable. Anterra invests across the supply chain, from precision farming to consumer safety, typically taking significant minority equity positions and actively supporting management teams. They target investments of EUR 1M to EUR 15M per company, with a long-term investment horizon.

Adam Anders

Co-Founder and Managing Partner

Philip Austin

Co-Founder and Managing Partner

Maarten Goossens

Co-Founder and Partner

Dudley Hawes

Partner

Jacqueline Heard

Venture Partner

Yoran Meijers

Associate

Michael Widmann

Associate

Brett Wong

Principal

Past deals in Pets

Dalma

Series B in 2025
Dalma is an animal insurance company focused on providing pet owners with transparent, subscription-based health insurance. The company’s platform is designed to be user-friendly, offering coverage that reimburses costs associated with illnesses, injuries, and preventive care for pets. In addition to financial support, Dalma also provides customers with free unlimited access to veterinary advice and tips, facilitating better care for their animals. Through its digital approach, Dalma aims to simplify the insurance process for pet owners and enhance their overall experience in managing their pets' health.

Dalma

Series B in 2024
Dalma is an animal insurance company focused on providing pet owners with transparent, subscription-based health insurance. The company’s platform is designed to be user-friendly, offering coverage that reimburses costs associated with illnesses, injuries, and preventive care for pets. In addition to financial support, Dalma also provides customers with free unlimited access to veterinary advice and tips, facilitating better care for their animals. Through its digital approach, Dalma aims to simplify the insurance process for pet owners and enhance their overall experience in managing their pets' health.

Animol Discovery

Series C in 2024
Animol Discovery is a biotechnology company focused on developing proprietary veterinary small molecules to address the medical needs of animals. Led by a team of experts with extensive experience in the animal health industry, Animol utilizes a unique technology platform that leverages DNA-encoded chemicals. This innovative approach allows for accelerated ultra-high throughput screening, enabling the simultaneous evaluation of target and anti-target activities. By streamlining the drug discovery process, Animol aims to deliver effective and innovative medicines tailored specifically for veterinary patients, ultimately improving treatment options available to pet owners.

Animol Discovery

Series B in 2023
Animol Discovery is a biotechnology company focused on developing proprietary veterinary small molecules to address the medical needs of animals. Led by a team of experts with extensive experience in the animal health industry, Animol utilizes a unique technology platform that leverages DNA-encoded chemicals. This innovative approach allows for accelerated ultra-high throughput screening, enabling the simultaneous evaluation of target and anti-target activities. By streamlining the drug discovery process, Animol aims to deliver effective and innovative medicines tailored specifically for veterinary patients, ultimately improving treatment options available to pet owners.

Dalma

Series A in 2023
Dalma is an animal insurance company focused on providing pet owners with transparent, subscription-based health insurance. The company’s platform is designed to be user-friendly, offering coverage that reimburses costs associated with illnesses, injuries, and preventive care for pets. In addition to financial support, Dalma also provides customers with free unlimited access to veterinary advice and tips, facilitating better care for their animals. Through its digital approach, Dalma aims to simplify the insurance process for pet owners and enhance their overall experience in managing their pets' health.

Animol Discovery

Series B in 2022
Animol Discovery is a biotechnology company focused on developing proprietary veterinary small molecules to address the medical needs of animals. Led by a team of experts with extensive experience in the animal health industry, Animol utilizes a unique technology platform that leverages DNA-encoded chemicals. This innovative approach allows for accelerated ultra-high throughput screening, enabling the simultaneous evaluation of target and anti-target activities. By streamlining the drug discovery process, Animol aims to deliver effective and innovative medicines tailored specifically for veterinary patients, ultimately improving treatment options available to pet owners.

Dalma

Series A in 2022
Dalma is an animal insurance company focused on providing pet owners with transparent, subscription-based health insurance. The company’s platform is designed to be user-friendly, offering coverage that reimburses costs associated with illnesses, injuries, and preventive care for pets. In addition to financial support, Dalma also provides customers with free unlimited access to veterinary advice and tips, facilitating better care for their animals. Through its digital approach, Dalma aims to simplify the insurance process for pet owners and enhance their overall experience in managing their pets' health.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Invetx

Series A in 2020
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Invetx

Series A in 2020
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Animol Discovery

Series A in 2020
Animol Discovery is a biotechnology company focused on developing proprietary veterinary small molecules to address the medical needs of animals. Led by a team of experts with extensive experience in the animal health industry, Animol utilizes a unique technology platform that leverages DNA-encoded chemicals. This innovative approach allows for accelerated ultra-high throughput screening, enabling the simultaneous evaluation of target and anti-target activities. By streamlining the drug discovery process, Animol aims to deliver effective and innovative medicines tailored specifically for veterinary patients, ultimately improving treatment options available to pet owners.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.